GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (OTCPK:MDNAF) » Definitions » Equity-to-Asset
中文

Medicenna Therapeutics (Medicenna Therapeutics) Equity-to-Asset : 0.80 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Medicenna Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Medicenna Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $13.89 Mil. Medicenna Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $17.34 Mil.

The historical rank and industry rank for Medicenna Therapeutics's Equity-to-Asset or its related term are showing as below:

MDNAF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.09   Med: 0.85   Max: 1
Current: 0.8

During the past 9 years, the highest Equity to Asset Ratio of Medicenna Therapeutics was 1.00. The lowest was 0.09. And the median was 0.85.

MDNAF's Equity-to-Asset is ranked better than
67.9% of 1564 companies
in the Biotechnology industry
Industry Median: 0.66 vs MDNAF: 0.80

Medicenna Therapeutics Equity-to-Asset Historical Data

The historical data trend for Medicenna Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics Equity-to-Asset Chart

Medicenna Therapeutics Annual Data
Trend Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.51 0.95 0.90 0.89 0.81

Medicenna Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.87 0.81 0.85 0.85 0.80

Competitive Comparison of Medicenna Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Medicenna Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicenna Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Medicenna Therapeutics's Equity-to-Asset falls into.



Medicenna Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Medicenna Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Equity to Asset (A: Mar. 2023 )=Total Stockholders Equity/Total Assets
=21.549/26.636
=

Medicenna Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=13.886/17.343
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicenna Therapeutics  (OTCPK:MDNAF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Medicenna Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicenna Therapeutics (Medicenna Therapeutics) Business Description

Traded in Other Exchanges
Address
2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.